Boiron SA (BOIR)

Currency in EUR
21.25
+0.05(+0.24%)
Real-time Data·
BOIR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
High dividend Yield
BOIR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
21.0021.70
52 wk Range
20.8533.45
Key Statistics
Prev. Close
21.2
Open
21.3
Day's Range
21-21.7
52 wk Range
20.85-33.45
Volume
4.55K
Average Volume (3m)
1.71K
1-Year Change
-32.38%
Book Value / Share
21.78
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BOIR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.00
Upside
+17.65%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Boiron SA Company Profile

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.

Employees
2620
Market
France

Compare BOIR to Peers and Sector

Metrics to compare
BOIR
Peers
Sector
Relationship
P/E Ratio
32.5x16.1x−0.5x
PEG Ratio
−0.490.200.00
Price/Book
1.0x2.1x2.6x
Price / LTM Sales
0.8x3.1x3.3x
Upside (Analyst Target)
15.2%21.1%43.4%
Fair Value Upside
Unlock10.6%7.1%Unlock

Analyst Ratings

0 Buy
0 Hold
1 Sell
Ratings:
1 analysts
Overall Consensus
Sell

Analysts 12-Month Price Target:

Average 25.00
(+17.65% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.65%
Dividend Yield
5.66%
Industry Median 4.37%
Annualised payout
1.20
Paid annually
5-Years Growth
+2.71%
Growth Streak

Earnings

Latest Release
May 30, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

BOIR Income Statement

People Also Watch

69.92
TEPRF
-0.77%
74.80
VETO
-0.53%
28.26
FDJU
+0.28%
21.71
STMPA
+1.62%
61.75
AKE
+0.41%

FAQ

What Stock Exchange Does Boiron Trade On?

Boiron is listed and trades on the Paris Stock Exchange stock exchange.

What Is the Stock Symbol for Boiron?

The stock symbol for Boiron is "BOIR."

What Is the Boiron Market Cap?

As of today, Boiron market cap is 368.95M.

What Is Boiron's Earnings Per Share (TTM)?

The Boiron EPS (TTM) is 0.65.

When Is the Next Boiron Earnings Date?

Boiron will release its next earnings report on 02 Sept 2025.

From a Technical Analysis Perspective, Is BOIR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Boiron Stock Split?

Boiron has split 3 times.

How Many Employees Does Boiron Have?

Boiron has 2620 employees.

What is the current trading status of Boiron (BOIR)?

As of 08 Aug 2025, Boiron (BOIR) is trading at a price of 21.25, with a previous close of 21.20. The stock has fluctuated within a day range of 21.00 to 21.70, while its 52-week range spans from 20.85 to 33.45.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.